Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkyl carbamoyl 1,2,3-triazole-TSAO analogues

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 6, 1998, Pages 481-489

  Velazquez S ^a   Alvarez, R ^a   Perez C ^b   Gago, F ^b   De Clercq, E ^c   Balzarini, J ^c   Camarasa, M J ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

3' Spironucleosides; AIDS; Non nucleoside HIV 1 RT inhibitors; TSAO 1,2,3 triazoles

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AZIDE; PHOSPHORANE DERIVATIVE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0031791262     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900604     Document Type: Article

References (47)

1. Alonso R, Camarasa MJ, Alonso G & De las Heras FG (1980) Alkylating nucleosides. 5. Synthesis and cytostatic activity of N-ribosyl-halomethyl-1,2,3-triazoles. European Journal of Medicinal Chemistry 15:105-109.
2. Alvarez R, Jimeno ML, Pérez-Pérez MJ, De Clercq E, Balzarini J & Camarasa MJ (1997) Synthesis and anti-human immunodeficiency virus type 1 activity of novel 3′-spiro nucleoside analogues of TSAO-T. Antiviral Chemistry & Chemotherapy 8:507-509.
3. Alvarez R, Jimeno ML, Gago F, Balzarini J, Pérez-Pérez MJ & Camarasa MJ (1998) Novel 3′-spiro nucleoside analogues of TSAO-T. Part II. A comparative study based on NMR conformational analysis in solution and theoretical calculations. Antiviral Chemistry & Chemotherapy 9:123-133.
4. Alvarez R, Velázquez S, San-Félix A, Aquaro S, De Clercq E, Perno C-F, Karlsson A, Balzarini J & Camarasa MJ (1994) 1,2,3-Triazole-[2′,5′-bis-O-tert-butyldimethylsilyl-β-D- ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″- oxathiole-2″,2″-dioxide) (TSAO) analogues. Synthesis and anti-HIV-1 activity. Journal of Medicinal Chemistry 37:4185-4194.
5. Balzarini J, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, Bathurst IC, Barr PJ & De Clercq E (1992a) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1 specific nucleoside analogue 2′,5′-bis-O-(t-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) thymine (TSAO-T). Journal of Biological Chemistry 267:11831-11838.
6. Balzarini J, Pérez-Pérez MJ, San-Félix A, Schols D, Perno CF, Vandamme AM, Camarasa MJ & De Clercq E (1992b) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA 89:4392-4396.
7. Balzarini J, Pérez-Pérez MJ, San-Félix A, Velázquez S, Camarasa MJ & De Clercq E (1992c) [2′,5′-Bis-O-tert-butyldimethylsilyl)]-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 36:1073-1080.
8. Balzarini J, Karlsson A, Pérez-Pérez MJ, Vrang L, Walbers J, Zhang H, Öberg B, Vandamme AM, Camarasa MJ & De Clercq E (1993a) HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different ammo acid substitutions in the reverse transcriptase. Virology 192:246-253.
9. Balzarini J, Camarasa MJ & Karlsson A (1993b) TSAO derivatives: Highly specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors. Drugs of the Future 18:1043-1055.
10. Balzarini J, Kleim JP, Riess G, Camarasa MJ, De Clercq E & Karlsson A (1994) Sensitivity of (138 GLU → LYS) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochemical and Biophysical Research Communications 201:1305-1312.
11. Besler BH, Merz KM & Kollman PA (1990) Atomic charges derived from semiempirical methods. Journal of Computational Chemistry 11:431-439.
12. Bastide J, Hamelin J, Texier F & Quang YV (1973) Cycloaddition dipolaire-1,3 aux alcynes. Bulletin de la Societe Chimique de France 2998-3003.
13. Boyer PL, Ding J, Arnold E & Hughes SH (1994) Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 38:1909-1914.
14. Camarasa MJ, Pérez-Pérez MJ, San-Félix A, Balzarini J & De Clercq E (1992) 3́-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″, 2″-dioxide]pyrimidine nucleosides. Journal of Medicinal Chemistry 35:2721-12727.
15. Camarasa MJ, Pérez-Pérez MJ, Velázquez S, San-Félix A, Alvarez A, Ingate S, Jimeno ML, Karlsson A, De Clercq E & Balzarini J (1995) TSAO derivatives: highly specific inhibitors of human immunodeficiency virus type-1 (HIV-1) replication. Nucleosides and Nucleotides 14:585-594.
16. De Clercq E (1993) HIV-1 specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Medicinal Research Reviews 13:229-258.
17. De Clercq E (1995) Towards improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. Journal of Medicinal Chemistry 38:2491-2517.
18. De Clercq E (1996) Nonnucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Medicinal Research Reviews 16:125-157.
19. Dewar MJS, Zoebisch EG, Healy E F & Stewart JJP (1985) AM1: A new general purpose quantum mechanical molecular model. Journal of the American Chemical Society 107:3902-3909.
20. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK & Stuart DI (1997) Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proceedings of the National Academy of Sciences, USA 94:3984-3989.
21. García-López MT, García-Muñoz G, Iglesias J & Madroñero R (1969) Heterocyclic N-glycosides. III. Synthesis of N-glycosyl-v-triazoles from glycosyl azides and phenylacetylenes. Journal of Heterocyclic Chemistry 6:639-642.
22. Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. Journal of Medicinal Chemistry 28:849-857.
23. Goodsell DS & Olson AJ (1990) Automated docking of substrates to proteins by simulated annealing. Proteins Structure Function and Genetics 8:195-202.
24. Goodsell DS, Morris GM & Olson AJ (1996) Docking of flexible ligands: applications of autoDock. Journal of Molecular Recognition 9:1-15.
25. Harvey GR (1966) The reactions of phosphorous compounds. XII. A new synthesis of 1,2,3-triazoles and diazo esters from phosphorous ylids and azides. Journal of Organic Chemistry 31:1587-1590.
26. Hammerschmidt F, Polsterer JP & Zbiral E (1995) Synthesis of 1-(D-apio-β-D-furanosyl)-1,2,3-triazoles. Synthesis 415-418.
27. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, Williams RL, Kamer G, Ferris AL, Clark P, Hizi A, Hughes SH & Arnold E (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proceedings of the National Academy of Sciences, USA 90:6320-6324.
28. 138 → Lys on the p51 subunit. Journal of Biological Chemistry 269:25255-25258.
29. Katz RA & Skalka AM (1993) The retroviral enzymes. Annual Review of Biochemistry 63:133-173.
30. L'abbé G & Hassner A (1971) Stereochemistry XLIV. Regiochemistry in cycloaddition reactions of vinylazides with phenylacetylene. Bulletin des Societes Chimiques Belges 80:209-210.
31. Le Corre M (1970) Nouvelle voie d'accès aux esters α-cétoniques β-éthyléniques. Comptes Rendus de L'Academie des Sciences Serie C 270:1312-11314.
32. Morris GM, Goodsell DS, Huey R & Olson AJ (1996) AutoDock automated docking of flexible ligands to receptors, version 2.4. La Jolla: The Scripps Research Institute.
33. Nanni RG, Ding J, Jacobo-Molina A, Hughes SH & Arnold E (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspectives in Drug Discovery and Design 1:129-1150.
34. Pérez-Pérez MJ, San-Félix A, Balzarini J, De Clercq E & Camarasa MJ (1992) TSAO-analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. Journal of Medicinal Chemistry 35:2988-2995.
35. Ren JS, Esnouf R, Garman E, Jones Y, Somers D, Ross C, Kirby I, Keeling J, Darby G, Stuart D & Stammers D (1995) High resolution structure of HIV-1 RT: insights from four RT-inhibitor complexes. Nature Structural Biology 2:293-302.
36. Schörkuber W & Zbiral E (1980) Glycosylazide als Ausgangsbasis zur Gewinnung von Nucleosidanalogen. Liebigs Annalen 1455-1469.
37. Schörkuber W & Zbiral E (1981) Zur synthese von 5-(x-methyl)ribofuranosyl-1,2,3-triazol-nucleosides. Chemische Berichte 114:3165-3169.
38. Smerdon SJ, Jäger J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA & Steitz TA (1994) Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, USA 91:3911-3915.
39. Schinazi RF (1993) Competitive inhibitors of human immunodeficiency virus reverse transcriptase. Perspectives in Drug Discovery and Design 1:151-180.
40. Stewart JJP (1993) MOPAC 93. Tokyo: Fujitsu.
41. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PAJ & Arnold E (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. Journal of Molecular Biology 243:369-387.
42. Young S D (1993) Nonnucleoside inhibitors of HIV-1 reverse transcriptase. Perspectives in Drug Discovery and Design 1:181-192.
43. Vaishnav YN & Wong-Staal F (1991) The biochemistry of AIDS. Annual Review of Biochemistry 60:577-630.
44. Velázquez S, Chamorro C, Pérez-Pérez MJ, Alvarez R, Jimeno ML, Martín-Domenech A, Pérez C, Gago F, De Clercq E, Balzarini J, San-Félix A & Camarasa MJ (1998) Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse tanscriptase. Journal of Medicinal Chemistry 41:4636-4647
45. Velázquez S, Jimeno ML, Camarasa MJ & Balzarini J (1994) Synthesis of [1-[3′,5′-bis-O-tert-butyldimethylsilyl-β-D-arabino-and ribofuranosyl]cytosine]-2′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T. Tetrahedron 50:11013-11022.
46. Velázquez S, San-Félix A, Pérez-Pérez MJ, Balzarini J, De Clercq E &. Camarasa MJ (1993) TSAO analogues. 3. Synthesis and anti-HIV-1 activity of [2′,5′-bis-O-tert-butyldimethylsilyl-β-D-ribofuranosyl]- 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″, 2″-dioxide] purine and purine-modified nucleosides. Journal of Medicinal Chemistry 36:3230-3239.
47. Zbiral E (1974) Synthesen von heterocyclen mit hilfe von alkyliden-phosphoranen phosphin-imiden, vinyl phosphonium-salzen und vinylphosphin-oxiden. Synthesis 775-800.